Revolution Medicines Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Net loss: US$436.4m (loss widened by 76% from FY 2022). US$3.86 loss per share (further deteriorated from US$3.09 loss in FY 2022). RVMD Products In Clinical Trials Phase I: 4. Phase II: 1. All figures shown in the chart above are for the trailing 12 month (TTM) period Revolution Medicines Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) also missed analyst estimates by 11%. Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 5.0% from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 2 warning signs for Revolution Medicines you should be aware of, and 1 of them is potentially serious. Have feedback on this article? Concerned about the content? Get in touch with us directly. Altern
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $43.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- Revolution Medicines: An Expensive Shot At A Massive Market Opportunity [Seeking Alpha]Seeking Alpha
- Aptevo Therapeutics, TRACON Pharmaceuticals, BioSig Technologies among healthcare movers [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. (NASDAQ: RVMD) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $48.00 price target on the stock, up previously from $36.00.MarketBeat
- Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/26/24 - Miss
RVMD
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RVMD's page on the SEC website